A study to investigate pharmacokinetics and safety of rupatadine (10 mg) and its active metabolites in participants with hepatic impairment compared to matched control participants with normal hepatic function

2022-500774-34-00 Protocol DC08RUP/1/21 Human pharmacology (Phase I) - Other Ended

Start 8 Nov 2022 · End 9 Apr 2025 · Status Ended · 2 EU/EEA countries · 9 sites · Protocol DC08RUP/1/21

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 44
Countries 2
Sites 9

Urticaria

Key facts

Sponsor
Noucor Health S.A.
Participant type
Patients, Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Respiratory Tract Diseases [C08]
Trial duration
8 Nov 2022 → 9 Apr 2025
Decision date (initial)
2022-09-08
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Urticaria

VersionLevelCodeTermSystem organ class
20.0 PT 10046735 Urticaria 100000004858
21.1 LLT 10001723 Allergic rhinitis 10038738

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Noucor Health S.A.

Sponsor organisation
Noucor Health S.A.
Address
Avinguda Del Cami Reial 51-57
City
Palau-Solita I Plegamans
Postcode
08184
Country
Spain

Scientific contact point

Organisation
Noucor Health S.A.
Contact name
Daniel Peris

Public contact point

Organisation
Noucor Health S.A.
Contact name
Daniel Peris

Locations

2 EU/EEA countries · 9 investigational sites

By country

CountryMS statusPlanned subjectsSites
Portugal Ended 22 4
Spain Ended 22 5
Rest of world 0

Investigational sites

Portugal

4 sites · Ended
CCAB Centro Clinico Academico Braga Associacao
Gastroenterology Department, Lugar De Sete Fontes S Victor, 4710-243, Braga
Blueclinical Investigacao E Desenvolvimento Em Saude Lda.
BlueClinical Phase I, East Wing, Rua De Sarmento De Beires 153 3rd Floor 4 Floor, Porto
Hospital Pedro Hispano
Early Phase Clinical Trials Unit | ULSM+BlueClinical, Rua Doutor Eduardo Torres 1, 4450-113, Matosinhos
Centro Hospitalar De Vila Nova De Gaia Espinho
Early Phase Clinical Trial Unit | CHVNG/E + BlueClinical, Rua Conceicao Fernandes, 4434-502, Vila Nova De Gaia

Spain

5 sites · Ended
Hospital Universitario La Paz
Clinical Pharmacology, Paseo Castellana 261, 28046, Madrid
Hospital Universitario De La Princesa
Clinical Pharmacology, Calle De Diego De Leon 62, 28006, Madrid
Hospital Clinico San Carlos
Clinical Pharmacology, Calle Del Profesor Martin Lagos Sn, 28040, Madrid
Municipal Institute Of Medical Investigation
Unidad de Investigación Clínica del IMIM, Calle Del Doctor Aiguader 80, 08003, Barcelona
Hospital De La Santa Creu I Sant Pau
Gastroenterology Department, Calle De San Antonio Maria Claret 167, 08025, Barcelona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Portugal 2022-11-08 2025-04-03 2022-11-17 2025-03-14
Spain 2022-12-12 2025-04-09 2023-01-09 2025-03-26

Application history

10 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2022-06-03 Spain Acceptable
2022-07-26
2022-08-01
2 NON SUBSTANTIAL MODIFICATION NSM-1 2023-03-14 Spain Acceptable
2022-07-26
2023-03-14
3 SUBSTANTIAL MODIFICATION SM-1 2023-03-23 Spain Acceptable
2023-06-02
2023-06-02
4 SUBSTANTIAL MODIFICATION SM-2 2023-06-30 Acceptable 2023-08-22
5 NON SUBSTANTIAL MODIFICATION NSM-2 2024-01-16 Spain Acceptable 2024-01-16
6 SUBSTANTIAL MODIFICATION SM-3 2024-01-25 Spain Acceptable
2024-03-04
2024-03-04
7 SUBSTANTIAL MODIFICATION SM-4 2024-04-30 Spain Acceptable
2024-06-04
2024-06-05
8 SUBSTANTIAL MODIFICATION SM-5 2024-06-18 Spain Acceptable
2024-07-19
2024-07-19
9 SUBSTANTIAL MODIFICATION SM-6 2024-12-18 Spain Acceptable
2025-01-21
2025-01-21
10 NON SUBSTANTIAL MODIFICATION NSM-3 2025-02-05 Spain Acceptable
2025-01-21
2025-02-05